Keitumetse Majoro

Incidence and associated risk factors of anti-tuberculosis drug induced liver injury among TB patients

Vincent Aketch Nyangwara, Ziyaad Waja, Roslyn Stella Thelingwani, Raadhiya Osman et autres

BACKGROUND: Tuberculosis (TB) is a global health challenge. Use of anti-TB drugs to treat TB is associated with high prevalence of side effects that include anti-TB drug induced liver injury (ATDILI). The aim of this study was to determine the incidence and …

Afrique du Sud, Zimbabwe, us (code pays fourni par la source)

Incidence and associated risk factors of antituberculosis drug induced hepatotoxicity among TB patients

Vincent Aketch Nyangwara, Ziyaad Waja, Roslyn Stella Thelingwani, Raadhiya Osman et autres

Afrique du Sud, Zimbabwe (code pays fourni par la source)

Risk-stratified treatment for drug-susceptible pulmonary tuberculosis

Vincent K. Chang, Marjorie Z. Imperial, Patrick P. J. Phillips, Gustavo E. Velásquez et autres

The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was 12-month tuberculosis disease free survival, while the primary safety outcome was the …

us, Ouganda, gb, Afrique du Sud, vn, ht, Zimbabwe, in, br, Malawi, Kenya, pe, th (code pays fourni par la source)

Exhaled breath specimens subjected to point-of-care lipoarabinomannan testing

Firdaus Nabeemeeah, Tumelo Moloantoa, Ziyaad Waja, Ziska Pretorius et autres

International audience

Afrique du Sud, es, fr, us (code pays fourni par la source)